+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Discounting and decision making in the economic evaluation of health-care technologies



Discounting and decision making in the economic evaluation of health-care technologies



Health Economics 20(1): 2-15



Discounting costs and health benefits in cost-effectiveness analysis has been the subject of recent debate - some authors suggesting a common rate for both and others suggesting a lower rate for health. We show how these views turn on key judgments of fact and value: on whether the social objective is to maximise discounted health outcomes or the present consumption value of health; on whether the budget for health care is fixed; on the expected growth in the cost-effectiveness threshold; and on the expected growth in the consumption value of health. We demonstrate that if the budget for health care is fixed and decisions are based on incremental cost effectiveness ratios (ICERs), discounting costs and health gains at the same rate is correct only if the threshold remains constant. Expecting growth in the consumption value of health does not itself justify differential rates but implies a lower rate for both. However, whether one believes that the objective should be the maximisation of the present value of health or the present consumption value of health, adopting the social time preference rate for consumption as the discount rate for costs and health gains is valid only under strong and implausible assumptions about values and facts.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052641575

Download citation: RISBibTeXText

PMID: 21154521

DOI: 10.1002/hec.1612


Related references

Economic evaluation and decision-making in health. The role of economic evaluation in the adoption and spread of health technologies. 2008 SESPAS Report. Gaceta Sanitaria 22(Suppl. 1): 137-142, 2008

Economic decision making in healthcare. A standard approach to discounting health outcomes. Pharmacoeconomics 7(3): 198-205, 1995

The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 18(3): 341-364, 1999

Economic evaluation and health care decision-making. Health Policy 36(3): 215-229, 1996

Discounting in health care decision-making: time for a change?. Journal of Public Health Medicine 14(3): 250-256, 1992

How health economic evaluation (HEE) contributes to decision-making in public health care: the case of Brazil. Zeitschrift für Evidenz Fortbildung und Qualitat Im Gesundheitswesen 108(7): 405-412, 2014

Whither trial-based economic evaluation for health care decision making?. Health Economics 15(7): 677-687, 2006

Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion. Frontiers in Pharmacology 7: 252, 2016

Use of economic evaluation in local health care decision-making in England: a qualitative investigation. Health Policy 89(3): 261-270, 2009

Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. International Journal of Technology Assessment in Health Care 21(1): 1-14, 2005

Economic evaluation to inform health care decision-making: promise, pitfalls and a proposal for an alternative path. Social Science and Medicine 72(6): 832-839, 2011

Use of Economic Evaluations of Health Technologies In Dutch Healthcare Decision-Making: Barriers And Facilitators. Value in Health 18(7): A540, 2015

Discounting in the economic evaluation of health care interventions. Medical Care 31(5): 403-418, 1993

The discounting of ambiguous information in economic decision making. Journal of Behavioral Decision Making 16(5): 341-352, 2003

Economic Evaluation for The Decision Making Process of Implementing of Pharmaceutical Care for The Treatment of Hypertension In The Brazilian Health System: Stage I - Direct-Costs Analysis. Value in Health 18(7): A831, 2015